[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Bang SM, Cheong JW, Yang WI, Hahn JS: An unusual case of spontaneous remission of Hodgkin's disease after a single cycle of COPP-ABV chemotherapy followed by infectious complications. Yonsei Med J; 2005 Jun 30;46(3):425-30
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of spontaneous remission of Hodgkin's disease after a single cycle of COPP-ABV chemotherapy followed by infectious complications.
  • Advanced Hodgkin's disease is usually treated with six or more cycles of combination chemotherapy.
  • Spontaneous regression of the cancer is very rarely reported in patients with Hodgkin's disease.
  • We present an unusual case of a patient with Hodgkin's disease who experienced complete remission with a single cycle of chemotherapy, followed by pneumonia.
  • The case was a 36-year-old man diagnosed with stage IVB mixed cellularity Hodgkin's disease in November 2000.
  • After treatment with one cycle of COPP-ABV (cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine) chemotherapy without bleomycin, the patient developed interstitial pneumonia and was cared in the intensive care unit (ICU) for two months.
  • Follow-up chest computerized tomography (CT), performed during the course of ICU care, revealed markedly improved mediastinal lymphomatous lesions.
  • Furthermore, follow-up whole body CT and 18-fluorodeoxyglucose positron emission tomography showed complete disappearance of the lymphomatous lesions.
  • This report is followed by a short review of the literature on spontaneous regression of Hodgkin's disease.
  • To the best of our knowledge, this is the first case report of spontaneous remission of Hodgkin's disease in Korea.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Hodgkin Disease / complications. Hodgkin Disease / drug therapy. Pneumonia / complications. Prednisone / administration & dosage. Procarbazine / administration & dosage. Vinblastine / administration & dosage. Vincristine / administration & dosage
  • [MeSH-minor] Adult. Humans. Male. Remission, Spontaneous

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Pneumonia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2003 Feb;31(3):145-55 [12621474.001]
  • [Cites] Am J Hematol. 2003 Feb;72(2):153-4 [12555225.001]
  • [Cites] Leuk Lymphoma. 2004 Jan;45(1):171-4 [15061215.001]
  • [Cites] Yonsei Med J. 2004 Jun 30;45(3):527-32 [15227742.001]
  • [Cites] Cancer Res. 1966 Jun;26(6):1189-201 [5329907.001]
  • [Cites] Lancet. 1970 May 16;1(7655):1016-20 [4191629.001]
  • [Cites] Lancet. 1971 Mar 20;1(7699):593 [4100922.001]
  • [Cites] Cancer. 1980 May 15;45(10):2627-32 [7378996.001]
  • [Cites] Br Med J. 1980 Mar 29;280(6218):903 [7388364.001]
  • [Cites] Cancer. 1980 Nov 1;46(9):2093-9 [7427915.001]
  • [Cites] Lancet. 1981 May 16;1(8229):1112 [6112483.001]
  • [Cites] N Engl J Med. 1984 Dec 6;311(23):1471-5 [6548796.001]
  • [Cites] Cancer. 1988 Aug 15;62(4):791-4 [3395960.001]
  • [Cites] Am J Hematol. 1989 Jun;31(2):138-41 [2660545.001]
  • [Cites] Eur J Cancer. 1990;26(5):641-4 [2144756.001]
  • [Cites] Acta Oncol. 1990;29(5):545-50 [2206563.001]
  • [Cites] CA Cancer J Clin. 1993 Nov-Dec;43(6):327-46 [8242436.001]
  • [Cites] Cancer. 1994 Dec 1;74(11):3023-8 [7954265.001]
  • [Cites] J Clin Immunol. 1996 Nov;16(6):334-9 [8946278.001]
  • [Cites] Cancer Treat Rev. 1996 Nov;22(6):395-423 [9134002.001]
  • [Cites] Cancer Res. 1946 Apr;6:205-16 [21018724.001]
  • [Cites] Hematology. 2003 Jun;8(3):191-6 [12745644.001]
  • (PMID = 15988816.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CVPPABO protocol
  • [Number-of-references] 22
  • [Other-IDs] NLM/ PMC2815821
  •  go-up   go-down


2. Al-Shemmari SH, Al-Humood S, Ameen R, Kamlesh S, Nemec J, Varghese A: Hodgkin's disease: Kuwait experience. Med Princ Pract; 2004 Jul-Aug;13(4):201-5
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's disease: Kuwait experience.
  • OBJECTIVE: To describe histologic subtypes, clinical presentation and treatment outcome of Hodgkin's lymphoma in Kuwait.
  • SUBJECTS AND METHOD: Patients older than 15 years, diagnosed with Hodgkin's lymphoma between 1980 and 1998, were included in this retrospective analysis.
  • Data were collected using a standardized form that included demographics, histologic subtypes, clinical presentation, stage, extranodal involvement, treatment modality and follow-up.
  • Dominant histologic subtypes were nodular sclerosis 65 (46.4%) and mixed cellularity 42 (30%).
  • Disease-free survival according to treatment groups were: radiotherapy alone 100%, chemotherapy alone 88%, and combined modality 65%.
  • The 5-year Kaplan-Meier estimates of overall disease-free survival was 84%.
  • CONCLUSION: In the cohort of 137 patients with Hodgkin's disease the treatment with combined radiotherapy and chemotherapy had a remarkable outcome.
  • However, evaluation of long-term treatment complications is needed.
  • [MeSH-major] Hodgkin Disease
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Kuwait / epidemiology. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 S. Karger AG, Basel
  • (PMID = 15181324.001).
  • [ISSN] 1011-7571
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


3. Iraj AK: Hodgkin's disease: assessment of treatment and survival rates in Iran. Asian Pac J Cancer Prev; 2004 Oct-Dec;5(4):379-82
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's disease: assessment of treatment and survival rates in Iran.
  • BACKGROUND AND OBJECTIVE: Each year an estimated of 7,500 new cases of Hodgkin's disease are reported in the United States.
  • It is a type of malignancy, where 75% of patients can recover and be cured with modern therapeutic approaches if presentation is in an early stage.
  • The main objective of this investigation was to assess the current situation with the disease in Iran, with determination of 5- and 10-year-survival rates.
  • The information obtained through medical files was organized and the rate of response to treatment and overall survival (OS) were computed.
  • Mixed cellularity (47.2%) accounted for the most common histological subtype.
  • Complete remission was achieved with the ABVD chemotherapy regimen, included in 37.6% of overall chemotherapy regimens.
  • CONCLUSION: Chemotherapy was a significantly more effective treatment compared to other modalities, and provided complete remission in 52.7% of patients.
  • As general conclusions, early diagnosis, on time management of the patients, and use of appropriate treatment modalities provide significant prevention of mortality in Hodgkin's disease patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Hodgkin Disease / drug therapy. Hodgkin Disease / mortality
  • [MeSH-minor] Adult. Combined Modality Therapy. Cross-Sectional Studies. Disease-Free Survival. Female. Humans. Iran / epidemiology. Male. Retrospective Studies. Statistics, Nonparametric. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15546241.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


Advertisement
4. Xicoy B, Ribera JM, Miralles P, Berenguer J, Rubio R, Mahillo B, Valencia ME, Abella E, López-Guillermo A, Sureda A, Morgades M, Navarro JT, Esteban H, GESIDA Group, GELCAB Group: Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica; 2007 Feb;92(2):191-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma.
  • BACKGROUND AND OBJECTIVES: Although doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) is considered the standard chemotherapy regimen for Hodgkin's lymphoma (HL), information on the results of this therapy in human immunodeficiency (HIV)-related HL is scarce.
  • We analyzed the results of the ABVD regimen and highly active antiretroviral therapy (HAART) in patients with advanced stage, HIV-related HL.
  • Response to chemotherapy, overall survival (OS) and event-free survival (EFS) were recorded.
  • The histologic subtype of HL was nodular sclerosis in 17 patients (27%), mixed cellularity in 25 (41%), lymphocyte depletion in 10 (16%) and non-specified in the remaining 10 (16%).
  • INTERPRETATION AND CONCLUSIONS: In patients with advanced stage, HIV-related HL, treatment with ABVD together with HAART is feasible and effective.
  • This supports the concept that patients with HIV-related HL should be treated in the same way as immunocompetent patients if HAART, adequate supportive therapy and anti-infectious prophylaxis are given concomitantly.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Hodgkin Disease / drug therapy. Hodgkin Disease / virology. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. CD4-Positive T-Lymphocytes / metabolism. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Proportional Hazards Models. Treatment Outcome. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17296568.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


5. Linck D, Lentini G, Tiemann M, Fauser AA, Parwaresch R, Basara N: Sequential application of chemotherapy and monoclonal CD 20 antibody: successful treatment of advanced composite-lymphoma. Leuk Lymphoma; 2005 Feb;46(2):285-8
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential application of chemotherapy and monoclonal CD 20 antibody: successful treatment of advanced composite-lymphoma.
  • We describe successful treatment of a 38-year-old patient with composite lymphoma stage IV(A), who presented with multifocal enlarged lymph nodes.
  • The lymph node histology showed classic morphologic features of Hodgkin's disease, mixed cellularity subtype and follicular B-cell lymphoma.
  • The areas of Hodgkin's disease demonstrated positive immunoreactivity for CD30 and CD20 in the Hodgkin's cells.
  • Restaging after chemotherapy showed radiological partial remission, but biopsy confirmed persisting follicular B-cell lymphoma without bone marrow infiltration and no evidence of Hodgkin's disease.
  • He was treated with monoclonal CD 20-antibody (Rituximab) 10 mg/kg weekly for eight consecutive weeks due to marked positivity of CD 20-antigen in follicular lymphoma cells.
  • This treatment was well tolerated and final staging showed complete remission of the composite lymphoma.
  • This patient continues to be in remission 28 months after the end of the treatment.
  • In conclusion, in the very rare case of composite lymphoma a combination of chemotherapy and subsequent immunotherapy might be considered as a promising therapeutic option.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20. Hodgkin Disease / drug therapy. Hodgkin Disease / pathology. Humans. Ki-67 Antigen. Leukemia, Lymphoid / drug therapy. Leukemia, Lymphoid / pathology. Male. Neprilysin. Remission Induction / methods. Rituximab

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621815.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Ki-67 Antigen; 4F4X42SYQ6 / Rituximab; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


6. Adelusola KA, Titiloye NA, Rotimi O, Durosinmi M: Epstein Barr virus latent membrane protein-1 in Hodgkin's lymphoma in Nigerians. Afr Health Sci; 2009 Sep;9(3):174-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein Barr virus latent membrane protein-1 in Hodgkin's lymphoma in Nigerians.
  • The rest were non-Hodgkin's lymphoma (2 diffuse large B-cell and 1 null cell ALCL).
  • All were cases of classical HL with 60% being of the mixed cellularity (MC) subtype.
  • 60% of the tumour was EBV positive, all of the MC subtype.
  • Three patients had chemotherapy.
  • CONCLUSION: Mixed cellularity is the most common subtype and is the only subtype associated with EBV positivity in this study.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Hodgkin Disease / virology. Viral Matrix Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Antigens, CD15 / immunology. Antigens, CD30 / immunology. Biomarkers, Tumor / immunology. Child. Female. Hospitals, Teaching. Humans. Immunohistochemistry. Immunophenotyping. Male. Nigeria. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Pathol. 2000 Oct;53(5):262-9 [11091850.001]
  • [Cites] Histopathology. 2008 May;52(6):775-7 [18439160.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2114-20 [12796376.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):566-73 [12808062.001]
  • [Cites] Lancet Oncol. 2004 Jan;5(1):11-8 [14700604.001]
  • [Cites] Br J Haematol. 2004 May;125(3):267-81 [15086409.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] Afr J Med Med Sci. 1992 Oct;21(1):79-83 [1288248.001]
  • [Cites] Leukemia. 1994 Apr;8 Suppl 1:S77-82 [8152310.001]
  • [Cites] Br J Haematol. 2005 Jun;129(5):615-7 [15916683.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):55-62 [16007870.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):747-55 [16084943.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2444-51 [15941916.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7604-13 [16186595.001]
  • [Cites] Mutat Res. 2000 Apr;462(2-3):395-405 [11523539.001]
  • (PMID = 20589147.001).
  • [ISSN] 1729-0503
  • [Journal-full-title] African health sciences
  • [ISO-abbreviation] Afr Health Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Uganda
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Antigens, CD30; 0 / Biomarkers, Tumor; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Viral Matrix Proteins
  • [Other-IDs] NLM/ PMC2887026
  • [Keywords] NOTNLM ; Epstein-Barr virus / Hodgkin's lymphoma in Nigerians
  •  go-up   go-down


7. Cheong JW, Park SY, Roh JK, Suh CO, Hahn JS: Treatment of Hodgkin's disease: a twenty-year follow-up of patients at a center in Korea. Yonsei Med J; 2006 Aug 31;47(4):455-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of Hodgkin's disease: a twenty-year follow-up of patients at a center in Korea.
  • Hodgkin's disease (HD) is a hematologic malignancy which shows common features regardless of race, but racial differences may be considered with certain clinical characteristics.
  • HD in Korea shows somewhat different characteristics when compared to cases in Western countries.
  • We evaluated the clinical and histopathologic characteristics of HD, the outcomes of various chemotherapy regimens, and prognostic factors of HD in Korea.
  • One hundred and five patients with initial histopathologic diagnosis of Hodgkin's disease were retrospectively reviewed 20 years after diagnosis at Yonsei University College of Medicine.
  • Nodular sclerosis was the most common histopathologic subtype (41%) and mixed cellularity was nearly as common (40%).
  • The disease-free survival (DFS) and overall survival (OS) rate were 79.2% and 84.8% at 5-years, 70% and 79.2% at 10- and 20-years.
  • In conclusion, the survival rates of HD patients in our center were superior to those of previous reports in Korea and Western countries.
  • Considering the higher OS rate and decreased incidence of side effects, the ABVD regimen may be recommended for the initial treatment of Hodgkin's disease.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Humans. Korea. Male. Middle Aged. Prognosis. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 1992 Sep;3 Suppl 4:105-10 [1280463.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(5):859-65 [1555977.001]
  • [Cites] Yonsei Med J. 1997 Oct;38(5):270-84 [9409190.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):19-26 [9440718.001]
  • [Cites] Eur J Cancer. 2005 May;41(7):998-1006 [15862748.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6400-8 [16155026.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:81-5 [10707785.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):607-14 [12586796.001]
  • [Cites] Ann Intern Med. 1970 Dec;73(6):881-95 [5525541.001]
  • [Cites] Cancer. 1975 Oct;36(4):1241-9 [1100220.001]
  • [Cites] Cancer. 1975 Jul;36(1):252-9 [54209.001]
  • [Cites] Cancer Treat Rep. 1982 Mar;66(3):439-49 [7060033.001]
  • [Cites] Cancer Treat Rev. 1982 Mar;9(1):21-35 [6175409.001]
  • [Cites] Cancer Treat Rep. 1982 Apr;66(4):881-7 [6176323.001]
  • [Cites] Ann Intern Med. 1986 Jun;104(6):739-46 [2422994.001]
  • [Cites] J Clin Oncol. 1986 Sep;4(9):1295-306 [3528400.001]
  • [Cites] Cancer. 1987 Oct 15;60(8):1713-9 [3651998.001]
  • [Cites] Ann Intern Med. 1991 Mar 1;114(5):361-5 [1992877.001]
  • [Cites] J Clin Oncol. 1991 Aug;9(8):1409-20 [1712836.001]
  • [Cites] Ann Hematol. 1993 Mar;66(3):139-40 [7682448.001]
  • (PMID = 16941733.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2687724
  •  go-up   go-down


8. Milosević R, Colović M, Cemerikić-Martinović V, Colović N, Bogunović M: [Hodgkin's and Reed-Sternberg cells in the peripheral blood of a patient with advanced stage Hodgkin's disease]. Srp Arh Celok Lek; 2003 Sep-Oct;131(9-10):400-2
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hodgkin's and Reed-Sternberg cells in the peripheral blood of a patient with advanced stage Hodgkin's disease].
  • The occurrence of abnormal Hodgkin's and Reed-Sternberg cells in the peripheral blood in a patient suffering from Hodgkin's disease has been noticed exceptionally rare in a previous period, and especially rare in last ten years primarily due to successful treatment of this disease.
  • The analysis of mononuclear cells in rare patients with Hodgkin's disease was established that they belong to the B-lymphoid cells with expression of CD30 and CD15 antigens.
  • The examination of presence of Hodgkin's cells in the peripheral blood of patients with Hodgkin's disease is important for patients with advanced stage of the disease in which autologous stem cell transplantation and high dose chemotherapy is planned.
  • On histologic examination of lymph nodes, Hodgkin's disease, type nodular sclerosis with mixed cellularity was found.
  • The patient was in clinical stage IV/V of the disease and chemotherapy with 9 cycles of ABVD + Mp protocol was applied.
  • [MeSH-major] Hodgkin Disease / blood. Reed-Sternberg Cells
  • [MeSH-minor] Adult. Antigens, CD15 / analysis. Antigens, CD30 / analysis. Humans. Immunophenotyping. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15058220.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Yugoslavia
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Antigens, CD30
  •  go-up   go-down


9. Hirmiz K, Foyle A, Wilke D, Burrell S, Brownstone R, Ago C, Pahil R, Couban S: Intracranial presentation of systemic Hodgkin's disease. Leuk Lymphoma; 2004 Aug;45(8):1667-71
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial presentation of systemic Hodgkin's disease.
  • Intracranial involvement by Hodgkin's disease is rare.
  • We report a patient with Hodgkin's disease who had intracranial disease at presentation.
  • We also review the literature pertaining to intracranial Hodgkin's disease.
  • Using the key words "Hodgkin's disease" and "central nervous system (CNS) disease", we searched the Pubmed and Cancerlit databases.
  • References were systematically reviewed and data regarding the following variables was extracted: age, gender, signs and symptoms at presentation, histology of Hodgkin's disease, cerebrospinal fluid analysis, stage and treatment.
  • Only 36 cases of intracranial Hodgkin's disease were identified in the literature.
  • Intracranial Hodgkin's disease at presentation is even more uncommon with only 8 reported cases.
  • Most cases of intracranial involvement by Hodgkin's disease occur at the time of relapse.
  • The most common presenting feature of intracranial Hodgkin's disease is a cranial nerve palsy with brain parenchyma being the most common intracranial site of involvement.
  • Mixed cellularity histology is the most frequent subtype of Hodgkin's disease among these patients and the median survival following intracranial presentation is 46 months.
  • Treatment has varied extensively but includes whole brain radiation with or without combination chemotherapy.
  • Our literature review suggests that the prognosis is not dismal with appropriate treatment.
  • [MeSH-major] Brain Neoplasms / diagnosis. Hodgkin Disease / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Cranial Irradiation. Humans. Magnetic Resonance Imaging. Male. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15370222.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 36
  •  go-up   go-down


10. Hull MC, Mendenhall NP, Colgan ME: Subdiaphragmatic Hodgkin's disease: the University of Florida experience. Int J Radiat Oncol Biol Phys; 2002 Jan 1;52(1):161-6
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subdiaphragmatic Hodgkin's disease: the University of Florida experience.
  • PURPOSE: To assess the long-term outcomes and late effects of patients with subdiaphragmatic Hodgkin's disease.
  • METHODS AND MATERIALS: Twenty-one patients with Stage I and II subdiaphragmatic Hodgkin's disease were treated with curative intent between February 1966 and February 1998 at the University of Florida.
  • Patient characteristics were as follows: mean age, 38.7 years (range, 3-75 years); 20 males and 1 female; 33% lymphocyte predominant, 43% nodular sclerosing, 14% mixed cellularity, 5% lymphocyte depletion, and 5% unclassified Hodgkin's disease.
  • Treatment included inverted Y irradiation (InY) (8 patients), total nodal irradiation (TNI) (7 patients), and combined modality irradiation and chemotherapy (CMT) (6 patients).
  • There were no deaths from Hodgkin's disease.
  • Treatment failures occurred in 1 of 8 patients after InY, 1 of 7 after TNI, and 1 of 6 after CMT.
  • All 3 second solid malignancies in this study occurred 7-14 years after treatment in areas receiving 10-20 Gy.
  • CONCLUSIONS: Subdiaphragmatic Hodgkin's disease is an uncommon manifestation with excellent disease control achieved with InY, TNI, and CMT.
  • This subgroup of patients with Hodgkin's disease is predominantly male and older than subgroups with other presentations, which may predispose the group to a higher risk for serious adverse events after treatment.
  • We recommend InY with spleen for clinical Stages IA and nodular sclerosis or lymphocyte-predominant clinical Stage IIA, InY alone for pathologic Stages IA and IIA, and CMT for all Stage I/II patients with greater than three involved sites, B symptoms, bulky disease (>6 cm), central (para-aortic) presentation, or splenic involvement.
  • [MeSH-major] Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Diaphragm. Disease-Free Survival. Female. Florida. Follow-Up Studies. Humans. Inguinal Canal. Male. Mechlorethamine / administration & dosage. Middle Aged. Myocardial Infarction / etiology. Neoplasm Staging. Prednisone / administration & dosage. Procarbazine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11777634.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; VB0R961HZT / Prednisone; MOPP protocol
  •  go-up   go-down


11. Niu Y, Shi YK, He XH, Feng FY, Zhou LQ, Gu DZ: [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma]. Zhonghua Zhong Liu Za Zhi; 2008 Aug;30(8):630-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
  • OBJECTIVE: To compare the efficacy of chemotherapy alone, radiotherapy alone and combined-modality therapy in the treatment for early-stage Hodgkin's lymphoma (HL).
  • They were stratified into several groups based on initial treatment strategy: chemotherapy alone (CT group, n = 22), radiotherapy alone (RT group, n = 18), combined-modality therapy (CMT group, n = 109) and surgical resection (SR group, n = 1).
  • Chemotherapy regimens were mainly ABVD (adriamycin, bleomycin, vinblastine and dacarbazine) and MOPP (mechlorethamine, vincristine, procarbazine and prednisone).
  • RESULTS: The pathological types included nodular sclerosis (NS, n = 84), mixed-cellularity (MC, n = 39), lymphocyte-predominant (LP, n = 23), lymphocyte-depleted (LD, n = 3) and nodular lymphocyte predominant Hodgkin's disease (NLPHD, n = 1).
  • There were 33 patients with complete response (CR), 109 with partial response (PR), 5 with stable disease (SD) and 3 with progressive disease (PD) after initial therapy.
  • The overall 7-yr survival rate was 89.3%, and treatment failure rate at 6 years was 18.8%.
  • The response rate of CMT group was superior to that of CT group, and the patients with nodular sclerosis or mixed-cellularity type had significantly lower risk of treatment failure (P = 0.009 and 0.019, respectively).
  • The multivariate analysis revealed that the treatment strategies affected the prognosis significantly.
  • The risk of failure of chemotherapy alone was 2.52 times higher than that of combined-modality therapy (P = 0.004).
  • CONCLUSION: Combined-modality therapy is more effective than chemotherapy alone or radiotherapy alone in the treatment for early stage Hodgkin's lymphoma.
  • Though its acute adverse effects are more severe than that of chemotherapy or radiotherapy alone, it may reduce the risk of treatment failure.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Radiotherapy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Alopecia / chemically induced. Bleomycin / adverse effects. Bleomycin / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Dacarbazine / adverse effects. Dacarbazine / therapeutic use. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Leukopenia / chemically induced. Male. Mechlorethamine / adverse effects. Mechlorethamine / therapeutic use. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prednisone / adverse effects. Prednisone / therapeutic use. Procarbazine / adverse effects. Procarbazine / therapeutic use. Proportional Hazards Models. Remission Induction. Retrospective Studies. Survival Rate. Vinblastine / adverse effects. Vinblastine / therapeutic use. Vincristine / adverse effects. Vincristine / therapeutic use. Young Adult


12. Greco M, Valsecchi M, Niccodemi C, Presas J, Corrado C, Winkel M: [Limphomatous meningitis as recurrence site in Hodgkin's disease]. Medicina (B Aires); 2006;66(4):332-4
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Limphomatous meningitis as recurrence site in Hodgkin's disease].
  • [Transliterated title] Meningitis linfomatosa como sitio de recaída en la enfermedad de Hodgkin.
  • Intracraneal manifestations of Hodgkin's Disease (HD) are extremely rare, with an estimated incidence rate of approximately 0.5%.
  • 1) treatment-related leucoencephalopathy, 2) central nervous system infections, 3) paraneoplasic syndromes and 4) intracraneal lymphomas, which could be sub-classified into intraparenchymal or intradural masses.
  • We describe a case of a 40 year-old male with mixed cellularity type HD who developed neurological manifestations as relapsed disease.
  • The patient died from progressive disease refractory to third line chemotherapy.
  • We review the clinical features and differential diagnosis of leptomeningeal metastases in Hodgkin's disease.
  • [MeSH-major] Hodgkin Disease / pathology. Meningeal Neoplasms / secondary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dacarbazine / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Humans. Leukoencephalopathy, Progressive Multifocal / chemically induced. Leukoencephalopathy, Progressive Multifocal / pathology. Magnetic Resonance Imaging. Male. Paraneoplastic Syndromes / pathology. Prednisone / administration & dosage. Procarbazine / administration & dosage. Recurrence. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16977969.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Argentina
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; VB0R961HZT / Prednisone; ABVD protocol; BEACOPP protocol; ESHAP regimen
  •  go-up   go-down


13. Dadparvar S, Hussain R, Esteves F, Yu JQ, Grewal RK, Arif S, Cruz R, Barbaria CJ, Woods K, Styler MJ: Thallium-201 imaging in evaluation of Hodgkin's disease. Cancer J; 2002 Nov-Dec;8(6):469-75
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thallium-201 imaging in evaluation of Hodgkin's disease.
  • PURPOSE: The role of Ga 67 in the evaluation of Hodgkin's disease has been widely established.
  • This prospective study was performed to evaluate the role of Tl 201 imaging in Hodgkin's disease at the time of initial presentation and in the assessment of response to therapy, relapse, and remission.
  • METHODS: Fifty-one consecutive patients (23 female, 28 male) with known Hodgkin's disease underwent 111 Tl 201 and Ga 67 studies.
  • The histopathologies included nodular sclerosis (in 31 cases), mixed cellularity (in 12), lymphocytic predominant (in five), lymphocytic depletion (in one), and unknown (in two).
  • Comparison with Ga 67 imaging, anatomical imaging (computed tomography and/or magnetic resonance imaging), and clinical correlation were performed.
  • Tl 201 imaging was similar in sensitivity, specificity, and accuracy among the nodular sclerosis and the mixed-cellularity Hodgkin's disease.
  • CONCLUSION: Tl 201 imaging offers more specificity with a higher positive predictive value in the diagnosis of Hodgkin's disease.
  • The Ga 67 study is more sensitive than Tl 201 in the detection of disease.
  • Therefore, we recommend Tl 201 imaging in the initial evaluation and assessment of patients' response to radiation therapy and/or chemotherapy.
  • [MeSH-major] Hodgkin Disease / radionuclide imaging. Thallium Radioisotopes
  • [MeSH-minor] Adolescent. Adult. Female. Gallium Radioisotopes. Humans. Male. Middle Aged. Predictive Value of Tests. Prospective Studies. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12500856.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gallium Radioisotopes; 0 / Thallium Radioisotopes
  •  go-up   go-down


14. Schwartz CL: Special issues in pediatric Hodgkin's disease. Eur J Haematol Suppl; 2005 Jul;(66):55-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Special issues in pediatric Hodgkin's disease.
  • Childhood Hodgkin's disease (HD) is not a biologically unique disease; it differs from adult HD primarily in the relative incidence of disease histology.
  • Preadolescent children are more likely to have Mixed Cellularity and nodular lymphocyte predominant HD.
  • Adolescent and young adult HD is indistinguishable, with a predominance of nodular sclerosing (NS) HD.
  • Nonetheless, treatment paradigms have diverged over the years as pediatric oncologists responded first to developmental issues in the young child, and later to the long-term treatment consequences in all young survivors.
  • The latter concerns are of equal relevance to the young adult with HD.
  • The increasing convergence of treatment approaches in the past decade is therefore most appropriate.
  • Reproductive potential, risk of secondary malignancy and cardiopulmonary consequences of therapy have driven the pediatric treatment paradigm of care.
  • Chemotherapy with low dose, limited field radiation is standard, with low-stage patients often treated by chemotherapy alone.
  • Algorithms tailor therapy to response.
  • The prognostic importance of very early chemotherapy response rather than end-of-chemotherapy response has led the Children's Oncology Group to use early response (after 6 wk) to titrate individual therapy and dense regimens to maximize the early response rates.
  • Although the dose dense regimens of adult groups are similar, the pediatric algorithms emphasize using the enhanced efficacy to limit cumulative therapy.
  • This review intends to address the special issues of childhood HD, with the intent of further encouraging understanding that will foster convergence of pediatric and adult treatment paradigms.
  • [MeSH-major] Hodgkin Disease / pathology. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / standards. Child. Child, Preschool. Combined Modality Therapy / adverse effects. Combined Modality Therapy / standards. Humans. Infant. Infant, Newborn. Radiotherapy / adverse effects. Radiotherapy / standards

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16007870.001).
  • [ISSN] 0902-4506
  • [Journal-full-title] European journal of haematology. Supplementum
  • [ISO-abbreviation] Eur J Haematol Suppl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 80
  •  go-up   go-down


15. Msaad S, Yangui I, Ketata W, Ayoub A, Ayedi H: [Tracheal involvement revealing Hodgkin's disease. A case report]. Rev Pneumol Clin; 2007 Oct;63(5 Pt 1):323-5
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tracheal involvement revealing Hodgkin's disease. A case report].
  • [Transliterated title] Atteinte trachéale révélatrice d'une maladie de Hodgkin.
  • Inaugural tracheobronchitis is a rare but known manifestation of Hodgkin's disease.
  • Clinical signs are often misleading, retarding diagnosis and treatment.
  • We report a case of Hodgkin's disease revealed by wheezing with minimal hemoptysis.
  • Histology of the endoscopic biopsies demonstrated Hodgkin type infiltration of the trachea with mixed cellularity.
  • The patient was given chemotherapy and mediastinal radiotherapy and achieved complete remission.
  • [MeSH-major] Hodgkin Disease / diagnosis. Tracheal Neoplasms
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Bleomycin / therapeutic use. Bronchoscopy. Dacarbazine / therapeutic use. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Neoplasm Staging. Radiography, Thoracic. Radiotherapy Dosage. Remission Induction. Respiratory Sounds / etiology. Time Factors. Tomography, X-Ray Computed. Trachea / pathology. Vinblastine / therapeutic use

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166936.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


16. Harris MA, Radford JA, Deakin DP, James RD, Swindell R, Cowan RA: Limited field radiotherapy for early stage, infra-diaphragmatic Hodgkin's lymphoma. Clin Oncol (R Coll Radiol); 2004 Feb;16(1):53-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited field radiotherapy for early stage, infra-diaphragmatic Hodgkin's lymphoma.
  • AIMS: To analyse the treatment outcome for patients with stage I and II infra-diaphragmatic Hodgkin's lymphoma.
  • Twenty-five out of 33 patients received radiotherapy alone, three out of 33 patients received minimal initial chemotherapy (MIT) (4 weeks VAPEC B) and five patients received six cycles of ChlVPP EVA hybrid chemotherapy before radiotherapy.
  • Histological subtype was lymphocyte predominant (15/33), nodular sclerosis (11/33), mixed cellularity (4/33), lymphocyte-rich classical (1/33) and unclassifiable (2/33).
  • The median time to relapse was 37 months (range 7-65 months).
  • All five relapses had received radiotherapy alone and four were salvaged with chemotherapy.
  • There have been four second malignancies and one patient transformed to high-grade non-Hodgkin's lymphoma.
  • No patient has died of Hodgkin's lymphoma.
  • CONCLUSIONS: In our cohort of patients with infra-diaphragmatic stage I and II Hodgkin's lymphoma treated with limited-field radiotherapy, no patients died from uncontrolled disease.
  • The use of MIT may reduce the risk of relapse and obviate the need for conventional salvage chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / radiotherapy. Neoplasm Staging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Chlorambucil / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Prednisolone / administration & dosage. Procarbazine / administration & dosage. Retrospective Studies. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14768756.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 18D0SL7309 / Chlorambucil; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; ChlVPP-EVA regimen; VAPEC-B protocol
  •  go-up   go-down


17. Tsimberidou AM, Sarris AH, Medeiros LJ, Mesina O, Rodriguez MA, Hagemeister FB, Romaguera J, Pro B, McLaughlin P, Dang N, Cabanillas F: Hodgkin's disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcome. Leuk Lymphoma; 2001 May;41(5-6):535-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcome.
  • We report the frequency, presenting characteristics, progression-free survival, event-free survival, overall survival and AIDS-free survival of patients with previously untreated Hodgkin's disease (HD) in the setting of infection by human immunodeficiency virus (HIV).
  • Anderson Cancer Center between July 1985 and August 1999 with HD and HIV infection.
  • All available records were reviewed to determine presentation, clinical characteristics, treatment outcome, progression-free survival and overall survival.
  • We identified 887 patients with HD and 3,500 with Non-Hodgkin's Lymphoma (NHL).
  • The ratio of NHL to HD in HIV-negative versus HIV-positive patients was 3.9 versus 6.9, respectively.
  • There were 14 HIV-positive patients with HD and 97 with NHL.
  • The median age of the HIV-positive HD patients was 33 years, and 13 were male.
  • Three patients had Acquired Immune Deficiency syndrome (AIDS) at the time of HD diagnosis, and seven had B-symptoms.
  • Mixed cellularity histology was seen in eight, bone marrow involvement in five and extranodal disease in seven patients.
  • All patients received some antiretroviral therapy, but it was variable over the years.
  • Six patients died of complications arising from HIV infection, including one patient who had preexisting AIDS at HD presentation.
  • Two patients died of HD, without developing other conditions diagnostic of AIDS.
  • We conclude that in our referral patient population HIV infection is associated with preferential development of NHL rather than HD, which appears curable with standard treatment regimens.
  • Since HIV-related deaths exceed those caused by HD, future investigation should focus on integration of chemotherapy and highly active antiretroviral therapy.
  • [MeSH-major] Hodgkin Disease / virology. Lymphoma, AIDS-Related / epidemiology. Lymphoma, AIDS-Related / mortality
  • [MeSH-minor] Actuarial Analysis. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antiviral Agents / administration & dosage. Female. Humans. Incidence. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / virology. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11378571.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-16672
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antiviral Agents
  •  go-up   go-down


18. Saif MW, Hamilton JM, Allegra CJ: Varicella zoster meningitis preceeded by thrombophlebitis in a patient with Hodgkin's disease. Leuk Lymphoma; 2000 Oct;39(3-4):421-6
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Varicella zoster meningitis preceeded by thrombophlebitis in a patient with Hodgkin's disease.
  • Varicella zoster (V-Z) infections are common among patients with hematological malignancies, particularly Hodgkin's disease (HD).
  • The common denominator in both HD and V-Z infections is immunosuppression.
  • Most of V-Z infections occur in patients with HD during the remission period, who have mixed cellularity sub-type, with stage III disease and who have received combined chemo-radiation therapy.
  • The authors describe a case of HD who developed V-Z meningitis preceeded by superficial thrombophlebitis of upper extremities during the period of active chemotherapy.
  • [MeSH-major] Hodgkin Disease / virology. Meningitis, Viral / chemically induced. Thrombophlebitis / virology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Herpes Zoster / chemically induced. Humans. Immunocompromised Host. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11342324.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


19. Petera J, Macharová H, Pohanková R, Malír A, Coupek P, Konecný M, Patera J, Pecina J, Drbal J, Koukalová H, Vásová I: Radiotherapy of early stages Hodgkin's disease. 10 years experience of the Masaryk Memorial Cancer Institute. Neoplasma; 2000;47(2):129-32
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy of early stages Hodgkin's disease. 10 years experience of the Masaryk Memorial Cancer Institute.
  • Radiotherapy and chemotherapy, alone or in combination, are curative treatment methods in early stages of Hodgkin's disease (HD).
  • The choice of treatment depends on the stage of the disease, histological type and localization of the tumor, as well as on other prognostic factors.
  • A retrospective study was conducted including 145 patients with clinical Stages I and II of HD according to Ann Arbor classification, all treated in the Masaryk Memorial Cancer Institute in Brno during the years 1985 through 1994.
  • 41 patients were diagnosed with Stage IA tumor, 1 patient with Stage IB, 75 patients with Stage IIA and 28 with Stage IIB disease.
  • The histological types of the disease were lymphocyte predominant in 23 patients, nodular sclerosis in 49 patients, mixed cellularity in 65 cases and lymphocyte depletion in 8 cases.
  • 39 patients were treated with combination of radiotherapy and chemotherapy.
  • 15 patients were given chemotherapy alone, 7 patients from this group experienced a relapse.
  • The five-year survival was 81% in patients with Stages IA and IIA disease, 65% in Stages IB and IIB disease.
  • Radiotherapy remains the curative method of choice in highly selected group of patients with early stages of Hodgkin's disease.
  • The results of radiotherapy alone are unsatisfactory in unselected clinical Stage I--II patients because of the presence of patients with adverse prognostic factors, particularly B symptomatology, mixed cellularity/lymphocyte depletion histology, higher age.
  • These patients are candidates for combined treatment.
  • Modern equipment and meticulous treatment are conditions crucial for the outcome of curative radiotherapy in patients with Hodgkin's disease.
  • Combination chemotherapy is very effective in the treatment of relapse following the primary radiotherapy.
  • [MeSH-major] Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Child. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Mechlorethamine / administration & dosage. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Procarbazine / administration & dosage. Retrospective Studies. Survival Analysis. Treatment Outcome. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10985481.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] SLOVAKIA
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; COPP protocol; MOPP protocol; VBA protocol
  •  go-up   go-down


20. Gocheva L, Koleva I: Long-term outcome of treatment for Hodgkin's disease: the University Hospital Sofia experience. Klin Onkol; 2010;23(1):34-42
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of treatment for Hodgkin's disease: the University Hospital Sofia experience.
  • BACKGROUND: To establish the efficacy of the combined modality treatment (CMT) including curative extended field radiotherapy (EFRT) and chemotherapy (CHT) by examining the long-term outcome in Hodgkin's disease (HD) patients at the Sofia University Hospital "Queen Giovanna-ISUL", with particular focus on second primary malignancy (SPM), and to establish independent factors correlated with treatment outcome.
  • METHODS AND MATERIALS: Between 1982 and 2007, 170 patients with HD with median age of 12 years (range 3-40), (68 females, 102 males), were included in this retrospective study.
  • Histologic subtypes included lymphocyte predominance 7.6%, mixed cellularity 47.1%, nodular sclerosis 42.9% and lymphocyte depletion 0.6%.
  • The overall treatment consisted of both EFRT and CHT.
  • The daily dose was 1.5-2 Gy, the total dose for EFRT was 20-40 Gy.
  • RESULTS: Follow-up extended from a minimum of 0,3 years to maximum 25,7 years, with a median observation time 12 years.The 5-, 10-, 15-, and 25-year overall survival (OS) in the whole group was 93% : 86% : 82% : 82%, respectively.
  • In multivariate analysis, independent risk factors age < or = 15 years (p < 0.001), male gender (p = 0.005), daily dose < or = 1.5 Gy (p = 0.009), and total dose 26-30 Gy (p = 0.048) were found to positively affect OS.
  • We investigated a prognostic model, identifying groups of HD patients with particularly responsive disease, combining prognostic factors as age < or = 15 years (p = 0.001), male gender (p = 0.011), and total dose 26-30 Gy (p = 0.012).
  • CONCLUSION: The performed first Bulgarian study on CMT including EFRT and CHT exhibited a certain therapeutic potential in the treatment of HD patients, expressed in the achievement of high long term outcome and low SPM frequency.
  • [MeSH-major] Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Prognosis. Risk Factors. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20192072.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


21. Souza EM, Baiocchi OC, Zanichelli MA, Alves AC, Assis MG, Eiras DP, Dobo C, Oliveira JS: Impact of Epstein-Barr virus in the clinical evolution of patients with classical Hodgkin's lymphoma in Brazil. Hematol Oncol; 2010 Sep;28(3):137-41
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of Epstein-Barr virus in the clinical evolution of patients with classical Hodgkin's lymphoma in Brazil.
  • INTRODUCTION: Classical Hodgkin's Lymphoma (cHL) has been frequently associated with Epstein-Barr virus (EBV), which can be found in a latent pattern in Reed-Sternberg (RS) cells.
  • Patients were only included in this study if they had (1) >18 years, (2) negative HIV serology, (3) undergone similar chemotherapy protocols, (4) paraffin blocks available with enough material for systematic review and histological reclassification and for detection of EBV in RS cells by in situ hybridization and immunohistochemistry and (5) clinical, epidemiological and laboratorial parameters available after a thorough chart review.
  • Mixed cellularity (MC) subtype was more common in EBV-related tumours (25.5%) (p=0.005).
  • CONCLUSION: We demonstrate that the prevalence of EBV-related cHL in this Brazilian population is 52.5% and, that, the presence of EBV does not change the clinical evolution and OS of patients treated with similar chemotherapy protocols.
  • [MeSH-major] Epstein-Barr Virus Infections / pathology. Herpesvirus 4, Human / isolation & purification. Hodgkin Disease / virology
  • [MeSH-minor] Adolescent. Adult. Aged. Brazil. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 John Wiley & Sons, Ltd.
  • (PMID = 20128016.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


22. Coleman M, Kaufmann T, Nisce LZ, Leonard JP: Treatment of nonlaparotomized (clinical) stage I and II Hodgkin's disease patients by extended field and splenic irradiation. Int J Radiat Oncol Biol Phys; 2000 Mar 15;46(5):1235-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of nonlaparotomized (clinical) stage I and II Hodgkin's disease patients by extended field and splenic irradiation.
  • PURPOSE: At the New York Presbyterian Hospital-Cornell Medical Center, patients with unequivocal clinical stage I and IIA Hodgkin's disease (HD) have been treated with mantle, splenic, and extended field radiation therapy (EFRT) (without surgical staging).
  • METHODS AND MATERIALS: During the period 1971 to 1994, 94 patients with clinically staged HD, with favorable prognostic factors, were retrospectively reviewed.
  • Patients with pathological or equivocal staging, "B" symptoms, bulk disease, history of previous chemotherapy, and/or Stage III or IV disease were excluded from our analysis.
  • Nine of the relapses had nodular sclerosis histology, one had lymphocyte predominance, and none had mixed cellularity.
  • The median time to relapse was 38 months; mean time 42. 3 months.
  • All patients are alive, well and free of disease, including nine who received subsequent chemotherapy and one who underwent autotransplantation.
  • CONCLUSIONS: Careful clinical staging of early, asymptomatic HD patients treated with mantle, splenic, and EFRT may obviate the need for exploratory laparotomy.
  • [MeSH-major] Hodgkin Disease / radiotherapy. Spleen
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Recurrence. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10725636.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 07968
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  •  go-up   go-down


23. Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Kontopidou FN, Dimopoulou MN, Barbounis A, Grigorakis V, Karkantaris C, Anargyrou K, Chatziioannou M, Rombos J, Boussiotis VA, Vaiopoulos G, Kittas C, Pangalis GA: Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites. Eur J Haematol; 2001 Nov-Dec;67(5-6):279-88
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites.
  • BACKGROUND: Advanced Hodgkin's lymphoma (HL) is curable by conventional chemotherapy in 60--70% of patients.
  • The pretreatment identification of a sizeable subgroup of patients with sufficiently low failure-free survival (FFS) to be eligible for investigational treatment is necessary.
  • Most patients had nodular sclerosis (64%) and mixed cellularity (26%) histology.
  • [MeSH-major] Hodgkin Disease / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antibiotics, Antineoplastic / therapeutic use. Disease-Free Survival. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Predictive Value of Tests. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11872075.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic
  •  go-up   go-down


24. Smolewski P, Robak T, Krykowski E, Blasiñska-Morawiec M, Niewiadomska H, Pluzanska A, Chmielowska E, Zambrano O: Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution. Clin Cancer Res; 2000 Mar;6(3):1150-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution.
  • On the basis of a retrospective study of 327 patients with Hodgkin's disease (HD), the prognostic significance of several factors, accepted previously and recently proposed, has been analyzed with regard to response to treatment and the survival time.
  • The only independent, pretreatment factors negatively influenced by either time of survival or response to treatment were the following: age at diagnosis of more than 45 years, advanced (IIIB/IV) clinical stage, poor clinical status according to Karnofsky's scale (score less than 70), presence of systemic symptoms, mixed cellularity/lymphocyte depletion histological type, multisite peripheral nodal localization of the disease, abdominal lymphadenopathy, and large primary tumor mass (bulky disease).
  • Short time to achieve complete remission (during the first four courses of chemotherapy) has proven to be significantly positive predictive factor.
  • Cumulative dose of cytostatics lower than programmed was a significantly negative prognostic factor that correlated with a shorter time of survival.
  • High activity of serum lactate dehydrogenase correlated moderately with poor response to the first-line treatment but did not influence the survival time.
  • Other clinical, morphological, and biochemical parameters influenced neither the prognosis nor the response to treatment.
  • Additionally, immunohistochemical examinations for proliferating cell nuclear antigen and the protein products of the p53 and bcl-2 genes were performed on the lymph nodes obtained from the patients with HD.
  • High expression of proliferating cell nuclear antigen, p53, and BCL-2 correlated with poor response to the treatment and/or short time of survival.
  • Statistical analysis has led us to the conclusion that the pretreatment expression of these oncoproteins can be taken into consideration as a new prognostic factor in HD.
  • [MeSH-major] Hodgkin Disease / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Proliferating Cell Nuclear Antigen / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Retrospective Studies. Survival Analysis. Treatment Outcome. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Cancer Res 2000 May;6(5):2120
  • (PMID = 10741746.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


25. Perz JB, Giles C, Szydlo R, O'Shea D, Sanz J, Chaidos A, Wagner S, Davis J, Loaiza S, Marin D, Apperley J, Olavarria E, Rahemtulla A, Lampert I, Naresh K, Samson D, MacDonald D, Kanfer EJ: LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre. Bone Marrow Transplant; 2007 Jan;39(1):41-7
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.
  • High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a recognized treatment option for patients with relapsed Hodgkin's lymphoma.
  • We have analysed 67 patients who underwent ASCT after LACE (lomustine (CCNU), cytarabine (Ara-C), cyclophosphamide, etoposide) conditioning for relapsed (n=61) or primary refractory (n=6) Hodgkin's lymphoma.
  • The 100-day treatment-related mortality was 3%.
  • In multivariate analysis mixed cellularity classical or lymphocyte-depleted classical histology subtype and haemoglobin level of 10 g/dl or less at the time of ASCT were identified as risk factors for worse OS, whereas stage III or IV disease at diagnosis and disease status at ASCT other than complete or partial remission predicted inferior PFS.
  • LACE followed by ASCT is an effective treatment for the majority of patients with chemosensitive relapsed Hodgkin's lymphoma and a proportion of chemorefractory patients also benefit.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hodgkin Disease / therapy. Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Drug Resistance, Neoplasm. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Lomustine / administration & dosage. Male. Middle Aged. Recurrence. Retrospective Studies. Time Factors. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17115062.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 7BRF0Z81KG / Lomustine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


26. Wu SJ, Chen CY, Su IJ, Tang JL, Chou WC, Ko BS, Huang SY, Yao M, Tsay W, Chen YC, Wang CH, Tien HF: Clinical characteristics and treatment response of Hodgkin's lymphoma in Taiwan. J Formos Med Assoc; 2008 Jan;107(1):4-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and treatment response of Hodgkin's lymphoma in Taiwan.
  • BACKGROUND/PURPOSE: Hodgkin's lymphoma (HL) is particularly rare in Asia, including Taiwan.
  • The report concerning its clinical features and treatment outcomes in Asians is limited.
  • RESULTS: The age distribution revealed a young-adult peak at the age around 20 years.
  • The nodular sclerosis type (NS-HL) was the most common histopathologic subtype (45%), followed by mixed cellularity (29%), lymphocyte predominant (13%), and lymphocyte depleted subtype (2%).
  • Induction therapy led to complete remission (CR) in 87% of patients.
  • CONCLUSION: The treatment response of HL in Taiwan is good and comparable to that in Western countries.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18218572.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


27. Niitsu N, Okamoto M, Tomita N, Aoki S, Tamaru J, Miura I, Hirano M: Multicentre phase II study of the baseline BEACOPP regimen for patients with advanced-stage Hodgkin's lymphoma. Leuk Lymphoma; 2006 Sep;47(9):1908-14
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentre phase II study of the baseline BEACOPP regimen for patients with advanced-stage Hodgkin's lymphoma.
  • A German Hodgkin's lymphoma (HL) study group designed the BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisolone) regimen.
  • In the BEACOPP regimen, treatment intervals were shortened and the dose-intensity was increased compared with those in the ABVD regimen (doxorubicin, bleomycin, vinblastine and darcarbacine), resulting in a long-term disease-free survival rate of approximately 75-80%.
  • Between April 2001 and February 2004, 20 patients with HL of stage IIB or higher who had received no previous treatment were enrolled.
  • The histologic types were mixed cellularity in four cases and nodular sclerosis in 16 cases.
  • Adverse drug reactions were grade 4 neutropenia in 12 patients, grade 3-4 thrombocytopenia in seven patients, and grade 3 or higher non-hematologic toxicities in two patients (stomatitis in one patient and ALT/AST elevation in one patient).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bleomycin / therapeutic use. Cyclophosphamide / therapeutic use. Dacarbazine / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Procarbazine / therapeutic use. Treatment Outcome. Vinblastine / therapeutic use. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17065005.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol; BEACOPP protocol
  •  go-up   go-down


28. Miltényi Z, Gergely L, Illés A: [Chronic pericarditis in Hodgkin disease]. Orv Hetil; 2002 Dec 1;143(48):2687-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chronic pericarditis in Hodgkin disease].
  • [Transliterated title] Krónikus pericarditis Hodgkin-kórban.
  • INTRODUCTION: Among late complications of Hodgkin's disease's treatment the cardiovascular complications are important.
  • The incidence of the late onset (later than 48 months) of chronic pericardial disease is from 11 to 50% among patients with Hodgkin's disease with irradiation in the past history.
  • PURPOSE AND METHODS: Authors are presenting chronic constrictive pericarditis in a case among late consequences of therapy of Hodgkin's disease.
  • RESULTS (CASE REPORT): A male patient, who is 35 year old in the present, developed III/A2 clinical stage, mixed cellularity Hodgkin's disease in 1992.
  • He got combined chemotherapy and irradiation repeated and he came to complete remission.
  • Apart from the most frequent reasons of pericarditis and pericardial effusion, radiation induced, hypothyroid and primary manifestation of Hodgkin's disease equally arised.
  • Chronic constrictive pericarditis was proved by the histological evaluation of the pericardial tissue that was probably provoked by the mediastinal irradiation.
  • CONCLUSIONS: The early recognition and treatment of late complications are possible by the help of the patient's follow-up.
  • These complications of Hodgkin's disease with using of modern radiotherapy apparatus are usually avoided.
  • [MeSH-major] Hodgkin Disease / radiotherapy. Pericarditis, Constrictive / etiology
  • [MeSH-minor] Adult. Chronic Disease. Humans. Male. Pleural Effusion, Malignant / etiology. Pleural Effusion, Malignant / radiography. Radiotherapy / adverse effects. Radiotherapy Dosage. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12501578.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


29. Ramos Linares S, Breña Atienza J, Cháfer Rudilla M, Ríos Rull P, Cabello Rodríguez A, Merino Alonso J: Severe ifosfamide-induced neurotoxicity: a case report. Pharm World Sci; 2010 Apr;32(2):109-11
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Ifosfamide is an alkylating agent used in the treatment of several neoplasias.
  • CASE DESCRIPTION: We describe the case of a male with a mixed cellularity subtype classical Hodgkin's lymphoma, treated with ifosfamide after other chemotherapy drugs failure.
  • After the first Ifosfamide cycle, the patient showed severe neurological toxicity that resolved 3 weeks later with supportive therapy.
  • DISCUSSION: Among the risk factors described in the literature, our patient had previously received cisplatin chemotherapy, had low albumin serum levels, and had received ifosfamide as a rapid intravenous infusion.
  • The management of the neurotoxicity is symptomatic although some drugs, like methylene blue and albumin, have also been used.
  • [MeSH-minor] Adult. Hodgkin Disease / drug therapy. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Jan;82(2):291-4 [10646879.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Mar;19(2):108-14 [17355105.001]
  • [Cites] Anticancer Drugs. 2004 Apr;15(4):347-50 [15057138.001]
  • [Cites] Am J Clin Oncol. 2005 Jun;28(3):277-80 [15923801.001]
  • [Cites] Oncology. 2003;65 Suppl 2:7-10 [14586140.001]
  • [Cites] J Oncol Pharm Pract. 2006 Dec;12(4):237-9 [17156595.001]
  • [Cites] Oncology. 2003;65 Suppl 2:2-6 [14586139.001]
  • [Cites] Ann Pharmacother. 2006 Feb;40(2):299-303 [16391008.001]
  • [Cites] Haematologica. 2007 Jan;92(1):35-41 [17229633.001]
  • (PMID = 20033290.001).
  • [ISSN] 1573-739X
  • [Journal-full-title] Pharmacy world & science : PWS
  • [ISO-abbreviation] Pharm World Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


30. Kochbati L, Chraïet N, Nasr C, Boussen H, Touati S, Ben Romdhane K, Maalej M: [Hodgkin disease of the nasopharynx: report of three cases]. Cancer Radiother; 2006 May;10(3):142-4
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hodgkin disease of the nasopharynx: report of three cases].
  • [Transliterated title] Maladie de Hodgkin du cavum: à propos de trois cas.
  • We report three cases of Hodgkin's disease (HD) involving the nasopharynx.
  • Their clinical presentations, morphological and immunohistochimical features and their therapy modalities are discussed.
  • Histological study showed mixed cellularity type of HD in all cases.
  • HD of nasopharynx should be differentiated from EBV-associated lymphoproliferations.
  • The treatment is based on radiotherapy that can be associated to neoadjuvant chemotherapy if nodes are involved.
  • [MeSH-major] Hodgkin Disease. Nasopharyngeal Neoplasms
  • [MeSH-minor] Adult. Aged. Female. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16309942.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


31. O'Toole O, O'Hare A, Grogan L, Bolger C, Brett FM: 20 year old lady with a paraspinal mass. Brain Pathol; 2010 May;20(3):683-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient underwent emergency resection of the lesion and pathology revealed Hodgkin's Lymphoma (HL)-mixed cellularity type.
  • The patient is currently undergoing treatment with ABVD chemotherapy.
  • CNS-HL is extremely rare and may occur de novo or in association with systemic disease.
  • Lesions may be parenchymal or dural based and are usually intracranial with an increased risk of CNS involvement in HL-mixed-cellularity type as in our patient.
  • [MeSH-major] Cervical Vertebrae / pathology. Hodgkin Disease / pathology. Spinal Canal / pathology. Spinal Cord Neoplasms / pathology. Spinal Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20522095.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


32. Singh A, Thapar V, Prabhu R, Naresh K, Joshi A, Supe A: Isolated splenic lymphoma: an elusive preoperative diagnosis. Indian J Gastroenterol; 2000 Oct-Dec;19(4):184-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated splenic lymphoma: an elusive preoperative diagnosis.
  • Four patients underwent splenectomy for various clinical and radiological diagnoses and were found to have primary splenic lymphoma at surgery and histology.
  • The diagnosis was classical Hodgkin's lymphoma, mixed cellularity type (one case); marginal zone B-cell non-Hodgkin's lymphoma (one case); and large B cell type non-Hodgkin's lymphoma (two cases).
  • Mean follow up of these patients was 11 months; all patients received chemotherapy.
  • One patient died, of causes not related to the disease process.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / surgery. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / surgery. Splenic Diseases / diagnosis. Splenic Diseases / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Intraoperative Period. Male. Middle Aged. Preoperative Care. Splenectomy / methods. Splenectomy / mortality. Splenomegaly / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Spleen Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11059187.001).
  • [ISSN] 0254-8860
  • [Journal-full-title] Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
  • [ISO-abbreviation] Indian J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article
  • [Publication-country] INDIA
  •  go-up   go-down


33. Axdorph U, Porwit-Macdonald A, Sjøberg J, Grimfors G, Bjørkholm M: T-cell-rich B-cell lymphoma - diagnostic and therapeutic aspects. APMIS; 2002 May;110(5):379-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell-rich B-cell lymphoma - diagnostic and therapeutic aspects.
  • BACKGROUND: Morphologically, T-cell-rich B-cell lymphoma (TCRB-NHL) may be indistinguishable from Hodgkin's disease (HD).
  • TCRB-NHL is occasionally misdiagnosed and treated as HD.
  • PATIENTS AND METHODS: We have re-evaluated 251 tumour biopsies from patients aged > or =15 years with HD diagnosed 1985-1994.
  • Reclassification from HD to TCRB-NHL was done in 12 cases (5%).
  • RESULTS: Twelve cases of TCRB-NHL were initially subclassified as HD (lymphocyte predominance 5, nodular sclerosis 3, and mixed cellularity 4).
  • Of these 12 TCRB-NHL patients, 6 were given radiotherapy alone, 5 MOPP/ABVD or similar combination chemotherapy, and one patient combined modality treatment.
  • Male sex (p<0.05) and inguinal involvement (p<0.001) were significantly more frequent when TCRB-NHL patients receiving HD treatment (n=12) were compared with the remaining patients with confirmed (conf) HD, while no significant differences were seen with regard to stage, bone marrow infiltration, splenomegaly or cause-specific survival.
  • Similar results were achieved when all TCRB-NHL patients (n=18) were compared to conf HD patients.
  • Lymphoma cells in three samples stained positively for LMP-1.
  • CONCLUSION: Immunohistochemistry makes it possible to identify cases of TCRB-NHL that are morphologically difficult to distinguish from HD.
  • The outcome of TCRB-NHL patients treated as having HD was comparable with that of the remaining HD population.
  • [MeSH-major] Hodgkin Disease / diagnosis. Immunophenotyping / methods. Lymphoma, B-Cell / diagnosis. Proteins. T-Lymphocytes / cytology
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD / metabolism. Biopsy. Carrier Proteins / metabolism. Cytoskeletal Proteins. Diagnosis, Differential. Female. Granzymes. Humans. Immunohistochemistry. Intracellular Signaling Peptides and Proteins. LIM Domain Proteins. Lymphocytes, Tumor-Infiltrating / immunology. Male. Membrane Proteins / metabolism. Middle Aged. Poly(A)-Binding Proteins. RNA-Binding Proteins / metabolism. Retrospective Studies. Serine Endopeptidases / metabolism

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12076255.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antigens, CD; 0 / Carrier Proteins; 0 / Cytoskeletal Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / LIM Domain Proteins; 0 / Membrane Proteins; 0 / PDLIM7 protein, human; 0 / Poly(A)-Binding Proteins; 0 / Proteins; 0 / RNA-Binding Proteins; 0 / TIA1 protein, human; EC 3.4.21.- / GZMB protein, human; EC 3.4.21.- / Granzymes; EC 3.4.21.- / Serine Endopeptidases
  •  go-up   go-down






Advertisement